Ascendis to investigate new indications following EU approval

Ascendis Pharma is ready to sell its growth hormone for children in the EU after Thursday's approval from the European Commission, but more indications are on the drawing board.

Photo: Kevin Grønnemann / MedWatch

On Thursday, Danish biotech firm Ascendis Pharma could celebrate the EU Commission's formal approval of Lonapegsomatropin, previously dubbed Transcon hGH, which is a once-weekly injection for pediatric patients with growth hormone deficiency (GHD).

The company is already eyeing more indications for Transcon hGH, Ascendis Pharma informs MedWatch.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs